Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations

Co-occurring pathological mutations in non-small cell lung cancer (NSCLC) may account for clinical heterogeneity not explained by the single driver mutation model. The prognostic significance of various co-mutations and adjuvant treatment modalities has been explored in early-stage NSCLC, but there has not been a focus on the impact of smoking and EGFR co-mutations in early-stage NSCLC. This study aims to characterize the frequency of co-mutations in EGFR-mutated (EGFRm) early-stage resected NSCLC; to describe relationships between smoking history and co-mutation status; and to determine whether prognosis differs by co-mutation status and smoking status among patients with EGFRm NSCLC.